Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care

International Journal of Hematology

Volumn 96, Issue 1, 2012, Pages 26-33

  Stasi, Roberto ^a   Murali, Magaral ^b   Michel, Marc ^c   Viallard, Jean François ^d,e   Giagounidis, Aristoteles ^f   Janssens, Ann ^g   Legg, Jason ^h   Deuson, Robert ^h   Danese, Mark D ⁱ  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f ST JOHANNES HOSPITAL   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h AMGEN INC   (United States)

ⁱ Outcomes Insights Inc   (United States)

Author keywords

Bleeding; Platelets; Thrombocytopenia; Thrombopoietin

Indexed keywords

IMMUNOGLOBULIN; RHESUS D ANTIBODY; ROMIPLOSTIM; STEROID;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BRAIN HEMORRHAGE; COMPARATIVE STUDY; DRUG EFFICACY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENORRHAGIA; MULTICENTER STUDY; OPEN STUDY; ORAL BLEEDING; PETECHIA; POST HOC ANALYSIS; PURPURA; SKIN BRUISING; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

AGED; AGED, 80 AND OVER; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; STANDARD OF CARE; THROMBOPOIETIN;

EID: 84865041492     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1088-8     Document Type: Article

References (14)

1. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113: 6511-21.
2. Tarantino M, Sunkara U, George JN, Aledort LM, Guo M, Berger D, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:3422. (ASH Annual Meeting Abstracts).
3. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641-8.
4. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet. 2008;371:395-403. (Pubitemid 351181334)
5. Kuter DJ, Bussel J, Newland A, Wasser JS, Lyons RM, George JN, et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. Blood 2010;116 (ASH Annual Meeting Abstracts).
6. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113: 2161-71.
7. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889-99.
8. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40. (Pubitemid 26230668)
9. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence- based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-207.
10. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-86.
11. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica. 1993;78:35-40.
12. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144:409-15.
13. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372-82.
14. Michel M, Rauzy OB, Thoraval FR, Languille L, Khellaf M, Bierling P, et al. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center casecontrolled study. Am J Hematol. 2011;86:980-4.